Clinical Trial Update: Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1-2a dose-ranging study evaluating TLK286 in combination with docetaxel in platinum-resistant non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• TLK286

Snippet

Sponsor: Telik | Conditions: Carcinoma, Non-small-cell Lung | Phase 1, Phase 2 | Status: COMPLETED